{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:15:42Z","timestamp":1757618142978,"version":"3.44.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03224-5","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:00:25Z","timestamp":1748581225000},"page":"3678-3690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Potential Impact of Sotatercept on Long-Term Disability in Commercially Insured Patients with Pulmonary Arterial Hypertension in the United States: An Exercise in Actuarial Modeling"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8897-9339","authenticated-orcid":false,"given":"Anna","family":"Watzker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Alsumali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Dieguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jestinah","family":"Chevure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Lautsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"El-Kersh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"7","key":"3224_CR1","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.4187\/respcare.02252","volume":"58","author":"EA Demerouti","year":"2012","unstructured":"Demerouti EA, Manginas AN, Athanassopoulos GD, Karatasakis GT. Complications leading to sudden cardiac death in pulmonary arterial hypertension. Respir Care. 2012;58(7):1246\u201354.","journal-title":"Respir Care"},{"key":"3224_CR2","unstructured":"Skwire D, et al. Group Insurance. 8th ed. Actex Learning; 2021."},{"key":"3224_CR3","unstructured":"Goss S, Stephens M, Barriss J, Wall D. Session 5: LTD Experience trends: social security and private insurance. Society of actuaries disability webcast series. 2021. Available from: https:\/\/www.ssa.gov\/OACT\/presentations\/ocact_20211109.pdf"},{"issue":"111","key":"3224_CR4","first-page":"37138","volume":"81","author":"Social Security Administration","year":"2016","unstructured":"Social Security Administration. Revised medical criteria for evaluating respiratory system disorders. Final Rule Federal Register. 2016;81(111):37138\u201353.","journal-title":"Final Rule Federal Register"},{"key":"3224_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12170-020-00661-5","volume":"15","author":"JD Mayeux","year":"2021","unstructured":"Mayeux JD, Pan IZ, Dechand J, Jacobs JA, Jones TL, McKellar SH, Beck E, Hatton ND, Ryan JJ. Management of pulmonary arterial hypertension. Curr Cardiovasc Risk Rep. 2021;15:1\u201324.","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"3224_CR6","unstructured":"Highlights of Prescribing Information: Winrevair. U.S. Food and drug administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761363s000lbl.pdf. Accessed 24 Jul. 2024."},{"issue":"1","key":"3224_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12325-023-02684-x","volume":"41","author":"V Mclaughlin","year":"2024","unstructured":"Mclaughlin V, Alsumali A, Liu R, Klok R, Martinez EC, Nourhussein I, Bernotas D, Chevure J, Pausch C, De Oliveira PJ, Lautsch D. Population health model predicting the long-term impact of Sotatercept on morbidity and mortality in patients with Pulmonary Arterial Hypertension (PAH). Adv Ther. 2024;41(1):130\u201351.","journal-title":"Adv Ther"},{"key":"3224_CR8","unstructured":"American Academy of Actuaries. The roles of the actuary in the selection & application of actuarial models. 2022. Available from: https:\/\/www.actuary.org\/sites\/default\/files\/2023-02\/01_Models2.9.23.pdf"},{"issue":"16","key":"3224_CR9","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JS, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Gr\u00fcnig E, Kope\u0107 G. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388(16):1478\u201390.","journal-title":"N Engl J Med"},{"key":"3224_CR10","unstructured":"American Academy of Actuaries. Group long-term disability 2012 valuation table. Available from:\u00a0https:\/\/www.soa.org\/globalassets\/assets\/files\/resources\/experience-studies\/2013\/gltd-2012-valuation-table.xls. Accessed 2023 Nov 30."},{"key":"3224_CR11","unstructured":"Guzman G, Kollar M. Income in the United States: 2022. United States Census Bureau. https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2023\/demo\/p60-279.pdf. 2023 Sep 12."},{"key":"3224_CR12","unstructured":"Social Security Administration. Disability Benefits | you're approved. Available from:\u00a0https:\/\/www.ssa.gov\/benefits\/disability\/approval.html. Accessed 2024 Sep 16."},{"key":"3224_CR13","unstructured":"Social Security Administration. Retirement benefits. Available from:\u00a0https:\/\/www.ssa.gov\/pubs\/EN-05-10035.pdf. Accessed 2024 May 31."},{"key":"3224_CR14","first-page":"171","volume":"42","author":"MM Goldman","year":"1990","unstructured":"Goldman R. Pricing and underwriting of group disability income coverages. Trans Soc Actuaries. 1990;42:171\u2013215.","journal-title":"Trans Soc Actuaries"},{"key":"3224_CR15","unstructured":"Consumer Price Index US City Average. U.S. Bureau of labor statistics. Available from:\u00a0https:\/\/www.bls.gov\/regions\/northeast\/data\/consumerpriceindex_us_table.htm. Accessed Oct 9, 2024."},{"issue":"1","key":"3224_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40273-024-01427-2","volume":"43","author":"A Watzker","year":"2025","unstructured":"Watzker A, Alsumali A, Ferro C, Dieguez G, Park C, Lautsch D, El-Kersh K. Economic burden associated with pulmonary arterial hypertension in the United States. Pharmacoeconomics.\u00a02025;43(1):83\u201391.","journal-title":"Pharmacoeconomics"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03224-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03224-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03224-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:26:53Z","timestamp":1757176013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03224-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3224"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03224-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna Watzker, Adnan Alsumali, Xun Jun Li, and Dominik Lautsch are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA at time of manuscript submission. Christine Ferro, Gabriela Dieguez, and Clare Park are employees of Milliman, Inc., who received consulting fees from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Jestinah Chevure is an employee of MSD (UK) Limited, a subsidiary of Merck & Co., Inc., London, UK at time of manuscript submission. Karim El-Kersh participated in United Therapeutics speaker\u2019s bureau 2018\u20132021 and served on advisory boards and as a consultant for United Therapeutics, J&J Actelion, Acceleron, and Merck & Co., Inc., Rahway, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on commercially available de-identified secondary data. Therefore, the study did not require patient IRB\/EC review and approval. The study did not require patient informed consent. This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}